Shots: The EC approval is based on P-III ATTR-ACT study assessing Vyndaqel (tafamidis meglumine, 20/80mg) vs PBO in patients with ATTR-CM that demonstrated a reduction in mortality and frequency of […]readmore
Tags : Tafamidis
Shots: The approval is based on P-III ATTR-ACT study assessing Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) vs PBO in patients with ATTR-CM The P-III ATTR-ACT study results: @30mos. reduction in […]readmore
Shots: ATTR-ACT is a P-III global study with three-arms 20mg or 80mg PO QD vs PBO, including patients with variant (ATTRm), wild-type (ATTRwt), or hereditary ATTR-ACT results (N=441): Reduced all-cause […]readmore